𝛼SK or Search

ENTITY

Jacobio Pharmaceuticals (1167 HK)

83

Analysis

Health Care • China

Jacobio Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to the in-house discovery and development of innovative oncology therapies, focusing on "undruggable" targets in key oncogenic pathways. They leverage their Induced Allosteric Molecule Discovery Platform and iADC Platform to develop novel drugs, including clinical-stage candidates like Glecirasib (KRAS G12C inhibitor) and Sitneprotafib (SHP2 inhibitor) for various solid tumors. The company was founded in 2015 and is headquartered in Beijing, China.

more

Refresh

Exchange Announcement • 24 Sep 2026 16:46

2026 Interim Report

Exchange Announcement • 24 Aug 2026 20:40

Interim Results Announcement For The Six Months Ended June 30, 2026 And Appointment Of Vice Chairperson Of The Board And Changes In Senior Management

Exchange Announcement • 12 Aug 2026 16:35

Date Of Board Meeting

Exchange Announcement • 10 Aug 2026 19:52

Positive Profit Alert

Exchange Announcement • 27 Jul 2026 06:42

Voluntary Announcement Jacobio Completed First Patient Dosage In The Phase Iia Clinical Trial Of Bet Inhibitor Jab-8263 In The Treatment Of Rheumatoid Arthritis In China

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x